Nicholas Bruchovsky

Summary

Affiliation: University of British Columbia
Country: Canada

Publications

  1. ncbi Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 107:389-95. 2006
  2. ncbi Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 109:858-67. 2007
  3. ncbi Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer
    Nicholas Bruchovsky
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, Canada
    Clin Genitourin Cancer 6:46-52. 2008
  4. ncbi Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy
    Jennifer A Locke
    The Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Can J Urol 17:5162-9. 2010
  5. ncbi Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells
    Natalie Blaszczyk
    Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:1860-9. 2004
  6. ncbi Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways
    Takeshi Ueda
    Department of Cancer Endocrinology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    J Biol Chem 277:7076-85. 2002
  7. ncbi Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells
    Takeshi Ueda
    Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada
    J Biol Chem 277:38087-94. 2002

Collaborators

Detail Information

Publications7

  1. ncbi Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 107:389-95. 2006
    ..This prospective Phase II study was undertaken to evaluate intermittent androgen suppression as a form of therapy in men with localized prostate cancer who failed after they received external beam irradiation...
  2. ncbi Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy
    Nicholas Bruchovsky
    The Prostate Center at Vancouver General Hospital, Division of Urology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
    Cancer 109:858-67. 2007
    ..Biochemical results from a prospective Phase II trial of intermittent androgen suppression for recurrent prostate cancer after radiotherapy were analyzed for correlations to the onset of hormone-refractory disease...
  3. ncbi Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer
    Nicholas Bruchovsky
    The Prostate Centre at Vancouver General Hospital, Department of Urologic Sciences, University of British Columbia, Canada
    Clin Genitourin Cancer 6:46-52. 2008
    ..Observations of quality of life (QOL), morbidity, and mortality were obtained from the results of a prospective phase II study of intermittent androgen suppression for recurrent prostate cancer after radiation therapy...
  4. ncbi Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy
    Jennifer A Locke
    The Prostate Centre at Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    Can J Urol 17:5162-9. 2010
    ..In the following study, we distinguish between these two possibilities and consider how the effectiveness of finasteride might be altered if androgens are synthesized within the malignant cell rather than the testis...
  5. ncbi Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells
    Natalie Blaszczyk
    Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:1860-9. 2004
    ..Here, we investigated the possibility that human osteoblasts might secrete factors that contribute to the emergence of androgen-independent prostate cancer...
  6. ncbi Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways
    Takeshi Ueda
    Department of Cancer Endocrinology, British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, British Columbia V5Z 4E6, Canada
    J Biol Chem 277:7076-85. 2002
    ..These results demonstrate that activation of the human AR NTD by IL-6 was mediated through MAPK and STAT3 signal transduction pathways in LNCaP prostate cancer cells...
  7. ncbi Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells
    Takeshi Ueda
    Department of Cancer Endocrinology, British Columbia Cancer Agency, Vancouver, British Columbia V5Z 4E6, Canada
    J Biol Chem 277:38087-94. 2002
    ..7) Ligand-independent activation of the AR did not occur by a mechanism of overexpression of either solely wild-type SRC-1 or mutant SRC-1 that mimics its phosphorylated form...